VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

SABCS 2020 | Advances in breast cancer coming in 2021

Nadia Harbeck, MD, PhD, LMU Munich, Munich, Germany discusses the need for new drugs in the HER2-positive metastatic space in 2021, as well as the potential clinical benefit of CDK46 inhibitors, AKT inhibitors, and abemaciclib for patients with HER2+, HER3+, and luminal breast cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter